AI assistant
VERTEX PHARMACEUTICALS INC / MA — Director's Dealing 2019
Feb 13, 2019
29864_dirs_2019-02-13_51314e41-83a0-4676-bddf-f58a810551ae.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK: 0000875320
Period of Report: 2019-02-11
Reporting Person: Arbuckle Stuart A (EVP\Chief Commercial Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2019-02-11 | Common Stock | S | 10657 | $179.44 | Disposed | 61280 | Direct |
| 2019-02-11 | Common Stock | S | 14915 | $180.34 | Disposed | 46365 | Direct |
| 2019-02-11 | Common Stock | S | 7501 | $181.03 | Disposed | 38864 | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 140 | Indirect |
Footnotes
F1: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1.
F2: Open market sales reported on this line occurred at a weighted average price of $179.44 (range $178.75 to $179.74).
F3: Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F4: Open market sales reported on this line occurred at a weighted average price of $180.34 (range $179.76 to $180.76).
F5: Open market sales reported on this line occurred at a weighted average price of $181.03 (range $180.77 to $181.59).